Pfizer Executive Angela Hwang Departs After 27 Years, Files Prospectus for New Venture

Dec 13, 2023 13:47 CST Updated 13:47

Pfizer

Pharmaceutical R&D Developer

On December 12, 2023, Pfizer announced,After working at Pfizer, Inc. for nearly 27 years,President of Pfizer Global BioPharmaceuticals Commercial GroupAngela HwangWill leave Pfizer. Huang Weiming has agreed to continue serving as a consultant to help Pfizer transition to the new model.

Official website information shows that Huang Weiming previously managed a team of 26,000 employees at Pfizer, shouldering the important task of delivering Pfizer's 600 drugs to patients in 189 countries. Under Huang Weiming’s leadership, Pfizer Biopharmaceuticals successfully developed the world’s first COVID-19 vaccine in 2020 and, a year later, the world’s first oral COVID-19 treatment, Paxlovid. In 2022, Pfizer Biopharmaceuticals achieved revenue of $100 billion, with more than half coming from the contributions of the COVID-19 vaccine and the COVID-19 treatment, Paxlovid.

Huang Weiming has consistently been recognized by top global business media such as Forbes and Fortune as one of the world's leading figures in healthcare and business, earning her a place among the 20 most influential women in business for three consecutive years.

Huang Weiming obtained a Bachelor of Science degree in Microbiology and Biochemistry from the University of Cape Town in South Africa and an MBA degree from Cornell University.

Source: PharmaCube

Disclaimer: The materials in this WeChat that are cited from other sources are reprinted for sharing purposes only and do not represent the platform's position. If there are any copyright issues, please contact us as soon as possible, and we will make corrections immediately. Thank you.